EDEN PRAIRIE, Minn., Oct. 30, 2017 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ:CHFS) announced today that on
October 27, 2017, the Company received formal notice from The NASDAQ Stock Market LLC indicating that the Company has regained
compliance with the minimum $1.00 bid price requirement, as set forth in Nasdaq Listing Rule 5550(a)(2), and the matter is now
closed.
About CHF Solutions
CHF Solutions, Inc. (NASDAQ:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for
Aquapheresis® therapy. The Aquadex FlexFlow system, is indicated for temporary (up to eight hours) ultrafiltration treatment of
patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of
patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a
healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company's
objective is to improve the quality of life for patients with heart failure and related conditions. CHF Solutions is a Delaware
corporation headquartered in Minneapolis with wholly owned subsidiaries in Australia and Ireland. The company has been listed on
the NASDAQ Capital Market since February 2012.
For further information, please contact:
Claudia Napal Drayton
Chief Financial Officer
CHF Solutions, Inc.
T: +1-952-345-4205
Investor Relations
CHF Solutions, Inc.
ir@chf-solutions.com
-or-
Bret Shapiro
Managing Partner
CORE IR
516 222 2560
brets@coreir.com
www.coreir.com
